SRPT Price Prediction Next Week
Analysis and Insights
News and Earnings Analysis:
Sarepta Therapeutics (SRPT) recently reported Q4 2024 earnings, with non-GAAP EPS of $1.90 missing estimates by $0.16, while revenue of $658.4 million exceeded expectations by $27.37 million. Despite the revenue beat, the stock fell due to higher expenses, with R&D and SG&A costs rising. The company also filed for a mixed shelf offering, indicating potential future fundraising activities.
Technical Indicators:
- RSI (14): 40.42, indicating the stock is not in oversold territory.
- MACD: Negative, suggesting bearish momentum.
- Bollinger Bands: The stock is trading near the lower band, indicating potential oversold conditions.
- SMA (20, 50, 200): The stock is below its 20 and 50-day moving averages, signaling bearish momentum.
Analyst Sentiment:
Analysts are mixed, with some maintaining Buy ratings (e.g., Evercore ISI with a $170 target) and others reiterating Sell ratings (e.g., H.C. Wainwright). Insider sentiment is negative, with increased selling activity.
Price Prediction:
Based on technical indicators and mixed earnings, SRPT is expected to decline. The stock is predicted to reach $98 next week.
Recommendation:
Sell SRPT as bearish technical indicators and mixed earnings suggest downward pressure.
SRPT Similar Chart Price Prediction
The price of SRPT is predicted to go up 16.67%, based on the high correlation periods with GRCE. The similarity of these two price pattern on the periods is 96.19%.
SRPT
GRCE
Up: 16.67%Similarity: 96.19%
SRPT Revenue Forecast
SRPT EPS Forecast
SRPT FAQs
What is SRPT revenue forecast for next quarter？
SRPT Analyst's Forecast
Louise Chen
Scotiabank
Hold
2025-03-07
Price Target
$105
Upside
+1.91%
Scotiabank analyst Louise Chen initiated coverage of Sarepta with a Sector Perform rating and $105 price target. The firm says that while Elevidys has been one of the best gene therapy launches to date, high expectations are already reflected in the stock. The analyst sees potential for downside risk to the shares if the uptake in non-ambulatory patients does not materialize or competitors announce positive updates to their Duchenne muscular dystrophy gene therapy programs.
Biren Amin
Piper Sandler
Buy
2024-11-27
Price Target
$200 → $182
Upside
+31.94%
Gil Blum
Needham
Strong Buy
2024-11-27
Price Target
$205 → $202
Upside
+46.44%
